Cited by 140Adipokines, Inflammation, and Metabolic DiseasesMuscle Physiology and DisordersAdipose Tissue and Metabolism

The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.

The effects of a soluble activin type IIB receptor on obesity and insulin sensitivity

Open access

Akpan, I, Goncalves, M D, Dhir, R, Yin, X, Pistilli, E E, Bogdanovich, S, Khurana, T S, Ucran, J, Lachey, J, Ahima, R S·2009·International Journal of Obesity

DOI 10.1038/ijo.2009.162PMC PMC2783781

Open this paper in CoChat — free account

Abstract

Background Myostatin, also known as Growth and Differentiation Factor 8, is a secreted protein that inhibits muscle growth. Disruption of myostatin signaling increases muscle mass and decreases glucose, but it is unclear whether these changes are related. We treated mice on chow and high-fat diets with a soluble activin receptor type IIB (ActRIIB, RAP-031), which is a putative endogenous signaling receptor for myostatin and other ligands of the TGF-beta superfamily.Results After 4 weeks, RAP-031 increased lean and muscle mass, grip strength and contractile force. RAP-031 enhanced the ability of insulin to suppress glucose production under clamp conditions in high-fat fed mice, but did not significantly change insulin-mediated glucose disposal. The hepatic insulin-sensitizing effect of RAP-031 treatment was associated with increased adiponectin levels. RAP-031 treatment for 10 weeks further increased muscle mass and drastically reduced fat content in mice on either chow or high-fat diet. RAP-031 suppressed hepatic glucose production and increased peripheral glucose uptake in chow-fed mice. In contrast, RAP-031 suppressed glucose production with no apparent change in glucose disposal in high-fat-diet mice.Conclusion Our findings show that disruption of ActRIIB signaling is a viable pharmacological approach for treating obesity and diabetes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/ijo.2009.162

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Inflammation and metabolic disorders
Hotamisligil, G. S. (2006) · Nature · doi:10.1038/nature05485 · Cited by 9,199
Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member
McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997) · Nature · doi:10.1038/387083a0 · Cited by 4,013
Obesity and insulin resistance
Kahn, B. B., & Flier, J. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10842 · Cited by 3,345
Adiponectin and Adiponectin Receptors
Kadowaki, T., & Yamauchi, T. (2005) · Endocrine Reviews · doi:10.1210/er.2005-0005 · Cited by 2,634
Muscle as an Endocrine Organ: Focus on Muscle-Derived Interleukin-6
Pedersen, B. K., & Febbraio, M. A. (2008) · Physiological Reviews · doi:10.1152/physrev.90100.2007 · Cited by 2,388
Double muscling in cattle due to mutations in the myostatin gene
McPherron, A. C., & Lee, S.-J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.23.12457 · Cited by 2,039
Dystrophin protects the sarcolemma from stresses developed during muscle contraction
Petrof, B. J., Shrager, J. B., Stedman, H. H., Kelly, A. M., & Sweeney, H. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3710 · Cited by 1,526
Myostatin Mutation Associated with Gross Muscle Hypertrophy in a Child
Schuelke, M., Wagner, K. R., Stolz, L. E., Hübner, C., Riebel, T., Kömen, W., Braun, T., Tobin, J. F., & Lee, S.-J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040933 · Cited by 1,399
Induction of Cachexia in Mice by Systemically Administered Myostatin
Zimmers, T. A., Davies, M. V., Koniaris, L. G., Haynes, P. A., Esquela‐Kerscher, A., Tomkinson, K. N., McPherron, A. C., Wolfman, N. M., & Lee, S. (2002) · Science · doi:10.1126/science.1069525 · Cited by 908
Functional improvement of dystrophic muscle by myostatin blockade
Bogdanovich, S., Krag, T. O. B., Barton, E. R., Morris, L. D., Whittemore, L.-A., Ahima, R. S., & Khurana, T. S. (2002) · Nature · doi:10.1038/nature01154 · Cited by 831
Self-citation

Flagged first, then by citations

Show all 39 references

1 of the 39 references couldn’t be matched to a known paper.

Sorted by citations

Muscle wasting in disease: molecular mechanisms and promising therapies
Cohen, S., Nathan, J. A., & Goldberg, A. L. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4467 · Cited by 1,089
Insulin resistance and sarcopenia: mechanistic links between common co-morbidities
Cleasby, M. E., Jamieson, P. M., & Atherton, P. J. (2016) · Journal of Endocrinology · doi:10.1530/joe-15-0533 · Cited by 596
Mitochondrial dysfunction in obesity
Bournat, J. C., & Brown, C. (2010) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32833c3026 · Cited by 488
Cancer cachexia: molecular mechanisms and treatment strategies
Setiawan, T., Sari, I. N., Wijaya, Y. T., Julianto, N. M., Muhammad, J. A., Lee, H., Chae, J. H., & Kwon, H. Y. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01454-0 · Cited by 342
Myostatin/activin pathway antagonism: molecular basis and therapeutic potential
Han, H. Q., Zhou, X., Mitch, W. E., & Goldberg, A. L. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.05.019 · Cited by 314
An Antibody Blocking Activin Type II Receptors Induces Strong Skeletal Muscle Hypertrophy and Protects from Atrophy
Lach-Trifilieff, E., Minetti, G. C., Sheppard, K., Ibebunjo, C., Feige, J. N., Hartmann, S., Brachat, S., Rivet, H., Koelbing, C., Morvan, F., et al. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01307-13 · Cited by 306
Activins and Inhibins: Roles in Development, Physiology, and Disease
Namwanje, M., & Brown, C. W. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a021881 · Cited by 294
Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia
Klimek, M. B., Aydogdu, T., Link, M., Pons, M., Koniaris, L. G., & Zimmers, T. A. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.12.123 · Cited by 229
Inhibition of myostatin in mice improves insulin sensitivity via irisin-mediated cross talk between muscle and adipose tissues
Dong, J., Dong, Y., Dong, Y., Chen, F., Mitch, W. E., & Zhang, L. (2016) · International Journal of Obesity · doi:10.1038/ijo.2015.200 · Cited by 212
Expression and function of myostatin in obesity, diabetes, and exercise adaptation
ALLEN, D. L., HITTEL, D. S., & MCPHERRON, A. C. (2011) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e3182178bb4 · Cited by 207
Emerging Roles for the Transforming Growth Factor-β Superfamily in Regulating Adiposity and Energy Expenditure
Zamani, N., & Brown, C. (2010) · Endocrine Reviews · doi:10.1210/er.2010-0018 · Cited by 214
Fatty acid metabolism, energy expenditure and insulin resistance in muscle
Turner, N. A., Cooney, G. J., Kraegen, E. W., & Bruce, C. R. (2013) · Journal of Endocrinology · doi:10.1530/joe-13-0397 · Cited by 206
Inhibition of myostatin protects against diet-induced obesity by enhancing fatty acid oxidation and promoting a brown adipose phenotype in mice
Zhang, C., McFarlane, C., Lokireddy, S., Masuda, S., Ge, X., Gluckman, P. D., Sharma, M., & Kambadur, R. (2012) · Diabetologia · doi:10.1007/s00125-011-2304-4 · Cited by 192
Myostatin and Sarcopenia: Opportunities and Challenges - A Mini-Review
White, T. A., & LeBrasseur, N. K. (2014) · Gerontology · doi:10.1159/000356740 · Cited by 191
Sarcopenic obesity and endocrinal adaptation with age
Sakuma, K., & Yamaguchi, A. (2013) · International Journal of Endocrinology · doi:10.1155/2013/204164 · Cited by 189
A single ascending‐dose study of muscle regulator ace‐031 in healthy volunteers
Attie, K. M., Borgstein, N. G., Yang, Y., Condon, C. H., Wilson, D. M., Pearsall, A. E., Kumar, R., Willins, D. A., Seehra, J. S., & Sherman, M. L. (2012) · Muscle & Nerve · doi:10.1002/mus.23539 · Cited by 178
Mechanisms Underlying Metabolic Syndrome-Related Sarcopenia and Possible Therapeutic Measures
Rubio-Ruiz, M. E., Guarner‐Lans, V., Pérez-Torres, I., & Soto, M. E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030647 · Cited by 174
Baf60c drives glycolytic metabolism in the muscle and improves systemic glucose homeostasis through Deptor-mediated Akt activation
Meng, Z.-X., Li, S., Wang, L., Ko, H. J., Lee, Y., Jung, D. Y., Okutsu, M., Yan, Z., Kim, J. K., & Lin, J. D. (2013) · Nature Medicine · doi:10.1038/nm.3144 · Cited by 146
Targeting the myostatin signaling pathway to treat muscle loss and metabolic dysfunction
Lee, S. (2021) · Journal of Clinical Investigation · doi:10.1172/jci148372 · Cited by 151
Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type
Cadena, S. M., Tomkinson, K. N., Monnell, T. E., Spaits, M. S., Kumar, R., Underwood, K. W., Pearsall, R. S., & Lachey, J. L. (2010) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00866.2009 · Cited by 138
Self-citation
Current understanding of sarcopenia: possible candidates modulating muscle mass
Sakuma, K., Aoi, W., & Yamaguchi, A. (2014) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-014-1527-x · Cited by 133
Novel Noninvasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy
Angelidi, A. M., Belanger, M. J., Kokkinos, A. D., Koliaki, C. C., & Mantzoros, C. S. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab034 · Cited by 141
Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism
Nunn, E., Jaiswal, N., Gavin, M., Uehara, K., Stefkovich, M., Drareni, K., Calhoun, R., Lee, M., Holman, C. D., Baur, J. A., et al. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.101880 · Cited by 126
Blockade of the Activin Receptor IIB Activates Functional Brown Adipogenesis and Thermogenesis by Inducing Mitochondrial Oxidative Metabolism
Fournier, B., Murray, B., Gutzwiller, S., Marcaletti, S., Marcellin, D., Bergling, S., Brachat, S., Persohn, E., Pierrel, E., Bombard, F., et al. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.06575-11 · Cited by 130
Myostatin: more than just a regulator of muscle mass
Argilés, J. M., Orpí, M., Busquets, S., & López-Soriano, F. J. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.02.001 · Cited by 125
Metabolic Functions of Myostatin and GDF11
McPherron, A. C. (2010) · Immunology Endocrine & Metabolic Agents - Medicinal Chemistry · doi:10.2174/187152210793663810 · Cited by 128
Exercise-induced myokines and their effect on prostate cancer
Kim, J., Galvao, D. A., Newton, R. U., Gray, E. S., & Taaffe, D. R. (2021) · Nature Reviews Urology · doi:10.1038/s41585-021-00476-y · Cited by 131
Prodomains regulate the synthesis, extracellular localisation and activity of TGF-β superfamily ligands
Harrison, C. A., Al-Musawi, S. L., & Walton, K. L. (2011) · Growth Factors · doi:10.3109/08977194.2011.608666 · Cited by 124
Metabolic benefits of resistance training and fast glycolytic skeletal muscle
LeBrasseur, N. K., Walsh, K. X., & Arany, Z. P. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00512.2010 · Cited by 123
Targeting the Activin Type IIB Receptor to Improve Muscle Mass and Function in the mdx Mouse Model of Duchenne Muscular Dystrophy
Pistilli, E. E., Bogdanovich, S., Goncalves, M. D., Ahima, R. S., Lachey, J. L., Seehra, J. S., & Khurana, T. S. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.11.071 · Cited by 116
Self-citation
Connecting Myokines and Metabolism
Ahima, R. S., & Park, H. K. (2015) · Endocrinology and Metabolism · doi:10.3803/enm.2015.30.3.235 · Cited by 111
Self-citation
A Novel Therapeutic Approach to Treating Obesity through Modulation of TGFβ Signaling
Koncarevic, A., Kajimura, S., Cornwall-Brady, M. R., Andreucci, A., Pullen, A. E., Sako, D., Kumar, R., Grinberg, A. V., Liharska, K., Ucran, J. A., et al. (2012) · Endocrinology · doi:10.1210/en.2012-1016 · Cited by 111
Self-citation
Mechanisms involved in the enhancement of mammalian target of rapamycin signalling and hypertrophy in skeletal muscle of myostatin‐deficient mice
Lipina, C., Kendall, H., McPherron, A. C., Taylor, P. M., & Hundal, H. S. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.04.039 · Cited by 98
Tbx15 controls skeletal muscle fibre-type determination and muscle metabolism
Lee, K. Y., Singh, M. K., Ussar, S., Wetzel, P., Hirshman, M. F., Goodyear, L. J., Kispert, A., & Kahn, C. R. (2015) · Nature Communications · doi:10.1038/ncomms9054 · Cited by 95
Increasing NAD Synthesis in Muscle via Nicotinamide Phosphoribosyltransferase Is Not Sufficient to Promote Oxidative Metabolism
Frederick, D. W., Davis, J. G., Dávila, A., Agarwal, B., Michán, S., Puchowicz, M. A., Nakamaru‐Ogiso, E., & Baur, J. A. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.579565 · Cited by 91
Myostatin is a key mediator between energy metabolism and endurance capacity of skeletal muscle
Mouisel, É., Relizani, K., Mille-Hamard, L., Denis, R., Hourdé, C., Agbulut, O., Patel, K., Arandel, L., Morales-Gonzalez, S., Vignaud, A., et al. (2014) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00377.2013 · Cited by 89
Bimagrumab improves body composition and insulin sensitivity in insulin‐resistant individuals
Garito, T., Roubenoff, R., Hompesch, M., Morrow, L., Gomez, K., Rooks, D., Meyers, C., Buchsbaum, M. S., Neelakantham, S., Swan, T., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13042 · Cited by 88
Myostatin: a skeletal muscle chalone
Lee, S.-J. (2023) · Annual Review of Physiology · doi:10.1146/annurev-physiol-012422-112116 · Cited by 84
Inhibition of myostatin and related signaling pathways for the treatment of muscle atrophy in motor neuron diseases
Abati, E., Manini, A., Comi, G. P., & Corti, S. P. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04408-w · Cited by 85
Pharmacological Inhibition of Myostatin and Changes in Lean Body Mass and Lower Extremity Muscle Size in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer
Padhi, D., Higano, C. S., Shore, N. D., SIEBER, P. R., Rasmussen, E., & Smith, M. R. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1271 · Cited by 83
Blockade of ActRIIB Signaling Triggers Muscle Fatigability and Metabolic Myopathy
Relizani, K., Mouisel, É., Giannesini, B., Hourdé, C., Patel, K., Morales-Gonzalez, S., Jülich, K., Vignaud, A., Piétri‐Rouxel, F., Fortin, D., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.90 · Cited by 79
Metabolic control of myofibers: promising therapeutic target for obesity and type 2 diabetes
Duan, Y., Li, F., Tan, B., Yao, K., & Yin, Y. (2017) · Obesity Reviews · doi:10.1111/obr.12530 · Cited by 81
Mechanisms involved in follistatin‐induced hypertrophy and increased insulin action in skeletal muscle
Han, X., Møller, L. L. V., Groote, E. D., Bojsen-Møller, K. N., Davey, J. R., Henríquez‐Olguín, C., Li, Z., Knudsen, J. R., Jensen, T. E., Madsbad, S., et al. (2019) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12474 · Cited by 75
Aerobic exercise + weight loss decreases skeletal muscle myostatin expression and improves insulin sensitivity in older adults
Ryan, A. S., Li, G., Blumenthal, J. B., & Ortmeyer, H. K. (2013) · Obesity · doi:10.1002/oby.20216 · Cited by 74
Inhibiting myostatin reverses muscle fibrosis through apoptosis
Li, Z. B., Zhang, J., & Wagner, K. R. (2012) · Journal of Cell Science · doi:10.1242/jcs.090365 · Cited by 74
Plasma follistatin is elevated in patients with type 2 diabetes: Relationship to hyperglycemia, hyperinsulinemia, and systemic low-grade inflammation
Hansen, J., Rinnov, A., Krogh‐Madsen, R., Fischer, C. P., Andreasen, A. S., Berg, R. M. G., Møller, K., Pedersen, B. K., & Plomgaard, P. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2415 · Cited by 71
A Soluble Activin Receptor Type IIB Prevents the Effects of Androgen Deprivation on Body Composition and Bone Health
Koncarevic, A., Cornwall-Brady, M., Pullen, A., Davies, M., Sako, D., Liu, J., Kumar, R., Tomkinson, K., Baker, T., Umiker, B., et al. (2010) · Endocrinology · doi:10.1210/en.2010-0134 · Cited by 71
Self-citation
Connecting the Metabolic and Immune Responses to Cancer
Flint, T. R., Fearon, D. T., & Janowitz, T. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.03.001 · Cited by 71
Akt deficiency attenuates muscle size and function but not the response to ActRIIB inhibition
Goncalves, M. D., Pistilli, E. E., Balduzzi, A., Birnbaum, M. J., Lachey, J., Khurana, T. S., & Ahima, R. S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012707 · Cited by 69
Self-citation
Postnatal PPARδ Activation and Myostatin Inhibition Exert Distinct yet Complimentary Effects on the Metabolic Profile of Obese Insulin-Resistant Mice
Bernardo, B. L., Wachtmann, T. S., Cosgrove, P. G., Kühn, M., Opsahl, A., Judkins, K. M., Freeman, T. B., Hadcock, J. R., & LeBrasseur, N. K. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011307 · Cited by 68
Increased Muscle Force Production and Bone Mineral Density in ActRIIB-Fc-Treated Mature Rodents
Chiu, C.-S., Peekhaus, N., Weber, H., Adamski, S., Murray, E. M., Zhang, H. Z., Zhao, J. Z., Ernst, R., Lineberger, J., Huang, L., et al. (2013) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glt030 · Cited by 68
Functional redundancy of type I and type II receptors in the regulation of skeletal muscle growth by myostatin and activin A
Lee, S.-J., Lehar, A., Liu, Y., Ly, C. H., Pham, Q.-M., Michaud, M., Rydzik, R., Youngstrom, D. W., Shen, M. M., Kaartinen, V., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2019263117 · Cited by 59
Relationship between myostatin and irisin in type 2 diabetes mellitus: a compensatory mechanism to an unfavourable metabolic state?
García-Fontana, B., Reyes‐García, R., Morales, S., Ávila-Rubio, V., Muñoz‐Garach, A., Rozas-Moreno, P., & Muñoz‐Torres, M. (2015) · Endocrine · doi:10.1007/s12020-015-0758-8 · Cited by 54
Myostatin — From the Mighty Mouse to cardiovascular disease and cachexia
Dschietzig, T. B. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.03.021 · Cited by 55
Local overexpression of the myostatin propeptide increases glucose transporter expression and enhances skeletal muscle glucose disposal
Cleasby, M. E., Jarmin, S., Eilers, W., Elashry, M. I., Andersen, D. K., Dickson, G., & Foster, K. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00586.2013 · Cited by 57
Antimyostatin Treatment in Health and Disease: The Story of Great Expectations and Limited Success
Nielsen, T. L., Vissing, J., & Krag, T. O. B. (2021) · Cells · doi:10.3390/cells10030533 · Cited by 53
Increasing muscle mass to improve metabolism
McPherron, A. C., Guo, T., Bond, N. D., & Gavrilova, O. (2013) · Adipocyte · doi:10.4161/adip.22500 · Cited by 59
The Baf60c/Deptor Pathway Links Skeletal Muscle Inflammation to Glucose Homeostasis in Obesity
Meng, Z., Wang, L., Xiao, Y., & Lin, J. D. (2014) · Diabetes · doi:10.2337/db13-1061 · Cited by 51
Over-expression of Follistatin-like 3 attenuates fat accumulation and improves insulin sensitivity in mice
Brandt, C., Hansen, R. H., Hansen, J. B., Olsen, C. H., Galle, P., Mandrup-Poulsen, T. R., Gehl, J., Pedersen, B. K., & Højman, P. (2014) · Metabolism · doi:10.1016/j.metabol.2014.10.007 · Cited by 51
Myostatin/Activin Receptor Ligands in Muscle and the Development Status of Attenuating Drugs
Rodgers, B. D., & Ward, C. W. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab030 · Cited by 111
Building muscle, browning fat and preventing obesity by inhibiting myostatin
LeBrasseur, N. K. (2012) · Diabetologia · doi:10.1007/s00125-011-2361-8 · Cited by 46
Myostatin and its association with abdominal obesity, androgen and follistatin levels in women with polycystic ovary syndrome
Chen, M., Han, D., Yang, J., Yang, Y., Ho, H., & Yang, W. (2012) · Human Reproduction · doi:10.1093/humrep/des209 · Cited by 44
Mammalian Mss51 is a Skeletal Muscle-Specific Gene Modulating Cellular Metabolism
Moyer, A. L., & Wagner, K. R. (2015) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-150119 · Cited by 43
Emerging drugs affecting skeletal muscle function and mitochondrial biogenesis – Potential implications for sports drug testing programs
Thevis, M., & Schänzer, W. (2016) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.7470 · Cited by 45
Anti-cytokine strategies for the treatment of cancer-related anorexia and cachexia
Penna, F., Minero, V. G., Costamagna, D., Bonelli, G., Baccino, F. M., & Costelli, P. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.503773 · Cited by 42
Sarcopenic Obesity: Involvement of Oxidative Stress and Beneficial Role of Antioxidant Flavonoids
Jung, U. J. (2023) · Antioxidants · doi:10.3390/antiox12051063 · Cited by 41
Estrogen sulfotransferase regulates body fat and glucose homeostasis in female mice
Khor, V. K., Dhir, R. N., Yin, X., Ahima, R. S., & Song, W. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00707.2009 · Cited by 38
Self-citation
Follistatin-derived peptide expression in muscle decreases adipose tissue mass and prevents hepatic steatosis
Nakatani, M., Kokubo, M., Ohsawa, Y., Sunada, Y., & Tsuchida, K. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00430.2010 · Cited by 34
A consensus guide to preclinical indirect calorimetry experiments
Banks, A. S., Allison, D. B., Alquier, T., Ansarullah, M., Austad, S. N., Auwerx, J. H., Ayala, J. E., Baur, J. A., Carobbio, S., Churchill, G. A., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01360-4 · Cited by 41
Long-term safety and tolerability of bimagrumab (BYM338) in sporadic inclusion body myositis
Sivakumar, K., Cochrane, T. I., Sloth, B., Ashar, H., Laurent, D., Tankó, L. B., & Amato, A. A. (2020) · Neurology · doi:10.1212/wnl.0000000000010417 · Cited by 32
The correlation of resistance exercise-induced myostatin with insulin resistance and plasma cytokines in healthy young men
Kazemi, F. (2015) · Journal of Endocrinological Investigation · doi:10.1007/s40618-015-0373-9 · Cited by 33
Effects of bimagrumab, an activin receptor type II inhibitor, on pituitary neurohormonal axes
Garito, T., Zakaria, M., Papanicolaou, D. A., Li, Y., Pinot, P., Petricoul, O., Laurent, D., Rooks, D., Rondon, J. C., & Roubenoff, R. (2018) · Clinical Endocrinology · doi:10.1111/cen.13601 · Cited by 31
Activin in Glucose Metabolism
Hashimoto, O., & Funaba, M. (2011) · Vitamins and hormones · doi:10.1016/b978-0-12-385961-7.00011-1 · Cited by 29
Effect of Myostatin Depletion on Weight Gain, Hyperglycemia, and Hepatic Steatosis during Five Months of High-Fat Feeding in Mice
Burgess, K., Xu, T., Brown, R. H., Han, B., & Welle, S. L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017090 · Cited by 28
The beneficial effect of myostatin deficiency on maximal muscle force and power is attenuated with age
Schirwis, E., Agbulut, O., Vadrot, N., Mouisel, É., Hourdé, C., Bonnieu, A., Butler-Browne, G. S., Amthor, H., & Ferry, A. (2012) · Experimental Gerontology · doi:10.1016/j.exger.2012.11.008 · Cited by 25
A Soluble Activin Receptor Type IIB Does Not Improve Blood Glucose in Streptozotocin-Treated Mice
Wang, Q., Guo, T., Portas, J., & McPherron, A. C. (2015) · International Journal of Biological Sciences · doi:10.7150/ijbs.10430 · Cited by 24
Soluble activin receptor type IIB treatment does not cause fat loss in mice with diet‐induced obesity
McPherron, A. C., Guo, T., Wang, Q., & Portas, J. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01520.x · Cited by 24
Pretreatment with a soluble activin type IIB receptor/Fc fusion protein improves hypoxia-induced muscle dysfunction
Pistilli, E. E., Bogdanovich, S., Mosqueira, M., Lachey, J. L., Seehra, J. S., & Khurana, T. S. (2009) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00138.2009 · Cited by 25
Self-citation
Generation of a Specific Activin Antagonist by Modification of the Activin A Propeptide
Makanji, Y., Walton, K. L., Chan, K. K. L., Gregorevic, P., Robertson, D. M., & Harrison, C. A. (2011) · Endocrinology · doi:10.1210/en.2011-1052 · Cited by 23
Decrease in myostatin by ladder-climbing training is associated with insulin resistance in diet-induced obese rats
Tang, L. V., Luo, K., Liu, C., Wang, X., Zhang, D., Chi, A., Zhang, J., & Sun, L. (2014) · Chinese Medical Journal · doi:10.3760/cma.j.issn.0366-6999.20140022 · Cited by 23
Myostatin regulates energy homeostasis through autocrine- and paracrine-mediated microenvironment communication
Wang, H., Guo, S., Gao, H., Ding, J., Li, H., Kong, X., Zhang, S., He, M., Feng, Y., Wu, W., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci178303 · Cited by 22
ActRIIB blockade increases force‐generating capacity and preserves energy supply in exercising mdx mouse muscle in vivo
Béchir, N., Pecchi, É., Vilmen, C., Fur, Y. L., Amthor, H., Bernard, M., Bendahan, D., & Giannesini, B. (2016) · The FASEB Journal · doi:10.1096/fj.201600271rr · Cited by 22
Why cellular stress suppresses adipogenesis in skeletal tissue, but is ineffective in adipose tissue: Control of mesenchymal cell differentiation via integrin binding sites in extracellular matrices
Volloch, V., & Olsen, B. R. (2013) · Matrix Biology · doi:10.1016/j.matbio.2013.06.001 · Cited by 21
Key factors involved in obesity development
Wang, Z., Yuan, D., Duan, Y., Li, S., & Hou, S. (2017) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-017-0428-3 · Cited by 19
Myostatin Regulates Tissue Potency and Cardiac Calcium-Handling Proteins
Jackson, M. F., Li, N., & Rodgers, B. D. (2014) · Endocrinology · doi:10.1210/en.2013-2014 · Cited by 18
Bimagrumab: an investigational human monoclonal antibody against activin type II receptors for treating obesity
Kaur, M., & Misra, S. (2024) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2024-0065 · Cited by 17
Silencing of activin receptor-like kinase 7 alleviates aortic stiffness in type 2 diabetic rats
Li, W., Zhao, J., Liu, L., Wang, Z., Han, L., Zhong, M., Zhang, Y., Zhang, W., & Tang, M. (2015) · Acta Diabetologica · doi:10.1007/s00592-014-0706-8 · Cited by 15
Inhibition of the Activin Receptor Type-2B Pathway Restores Regenerative Capacity in Satellite Cell-Depleted Skeletal Muscle
Formicola, L., Pannérec, A., Correra, R. M., Gayraud-Morel, B., Ollitrault, D., Besson, V., Tajbakhsh, S., Lachey, J. L., Seehra, J. S., Marazzi, G., et al. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00515 · Cited by 17
Self-citation
Mathematical Model of Muscle Wasting in Cancer Cachexia
Farhang‐Sardroodi, S., & Wilkie, K. P. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072029 · Cited by 16
Administration of a Soluble Activin Type IIB Receptor Promotes the Transplantation of Human Myoblasts in Dystrophic Mice
Fakhfakh, R., Lee, S.-J., & Tremblay, J. P. (2012) · Cell Transplantation · doi:10.3727/096368911x627480 · Cited by 15
Ski Overexpression in Skeletal Muscle Modulates Genetic Programs That Control Susceptibility to Diet‐Induced Obesity and Insulin Signaling
Diaz, M., Martel, N., Fitzsimmons, R. L., Eriksson, N. A., Cowin, G., Thomas, G. P., Cao, K. L., Muscat, G. E. O., & Leong, G. M. (2012) · Obesity · doi:10.1038/oby.2012.101 · Cited by 15
Myostatin inhibitors in sports drug testing: Detection of myostatin‐neutralizing antibodies in plasma/serum by affinity purification and Western blotting
Walpurgis, K., Thomas, A., Schänzer, W., & Thevis, M. (2015) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201500043 · Cited by 13
Does Activin Receptor Blockade by Bimagrumab (BYM338) Pose Detrimental Effects on Bone Healing in a Rat Fibula Osteotomy Model?
Tankó, L. B., Goldhahn, J., Varela, A., Lesage, E., Smith, S. Y., Pilling, A. M., & Chivers, S. (2016) · Calcified Tissue International · doi:10.1007/s00223-016-0148-0 · Cited by 12
Pharmacology of manipulating lean body mass
Sepulveda, P. V., Bush, E. D., & Baar, K. (2014) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12320 · Cited by 12
Myostatin's marvels: From muscle regulator to diverse implications in health and disease
Sharma, S., & Patil, A. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.4106 · Cited by 12
Development of antisense-mediated myostatin knockdown for the treatment of insulin resistance
Eilers, W., Cleasby, M. E., & Foster, K. (2021) · Scientific Reports · doi:10.1038/s41598-021-81222-7 · Cited by 13
Mitochondrial impairment induced by postnatal ActRIIB blockade does not alter function and energy status in exercising mouse glycolytic muscle in vivo
Béchir, N., Pecchi, É., Relizani, K., Vilmen, C., Fur, Y. L., Bernard, M., Amthor, H., Bendahan, D., & Giannesini, B. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00370.2015 · Cited by 11
Telmisartan versus metformin in downregulating myostatin gene expression and enhancing insulin sensitivity in the skeletal muscles of type 2 diabetic rat model
Tammam, A. A.-E., Rizg, W. Y., Boushra, A. F., Alhelf, M., Alissa, M., Soliman, G. F., Ouais, G. N., Hosny, K. M., Alkhalidi, H. M., & Elebiary, A. M. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1228525 · Cited by 10
Pharmacologic inhibition of myostatin with a myostatin antibody improves the skeletal muscle and bone phenotype of male insulin-deficient diabetic mice
Bunn, R. C., Adatorwovor, R., Smith, R. R., Ray, P. D., Fields, S. E., Keeble, A. R., Fry, C. S., Uppuganti, S., Nyman, J. S., Fowlkes, J. L., et al. (2023) · JBMR Plus · doi:10.1002/jbm4.10833 · Cited by 9
Inhibition of activin receptor 2 signalling ameliorates metabolic dysfunction–associated steatotic liver disease in western diet/L-NAME induced cardiometabolic disease
Swan, J., Szabó, Z., Peters, J., Kummu, O., Kemppi, A., Rahtu‐Korpela, L., Konzack, A., Hakkola, J., Pasternack, A. H., Ritvos, O., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116683 · Cited by 9

Authors: Akpan, I., Goncalves, M. D., Dhir, R., Yin, X., Pistilli, E. E., Bogdanovich, S., Khurana, T. S., Ucran, J., Lachey, J., & Ahima, R. S.
Affiliations: University of Pennsylvania Health System (US)
University of Pennsylvania (US)
Acceleron Pharma (United States) (US)
Corresponding author: Ahima, R S
ORCID: Akpan, I
Goncalves, M D
Dhir, R
Pistilli, E E
Bogdanovich, S
Khurana, T S
Ahima, R S
Venue: International Journal of Obesity
Publisher: Springer Science and Business Media LLC
Published: 2009-08-11
Volume: 33
Issue: 11
Pages: 1265-1273
ISSN: 0307-0565 (ISSN-L)
1476-5497
DOI: 10.1038/ijo.2009.162
PMC: PMC2783781
OpenAlex: W2050592095
Cited by: 140
References: 39
Citations by year: 2026: 4 · 2025: 1 · 2024: 8 · 2023: 7 · 2022: 4 · 2021: 8 · 2020: 9 · 2019: 6 · 2018: 4 · 2017: 4 · 2016: 7 · 2015: 12 · 2014: 17 · 2013: 12 · 2012: 10
FWCI: 8.28
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: International Journal of Obesity (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institute of Diabetes and Digestive and Kidney Diseases (P01DK049210, R01DK062348, P30 DK 19525, P30DK019525)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
Keywords: myostatin, obesity, insulin sensitivity, high-fat diet, hepatic glucose production, glucose uptake, muscle mass, adiponectin, TGF-beta superfamily, diabetes mellitus
MeSH terms: Animals, Insulin Resistance, Male, Mice, Inbred C57BL, Obesity, Solubility, Glucose Clamp Technique, Signal Transduction, Case-Control Studies, Muscle, Skeletal, Activin Receptors, Type II, Mice, Myostatin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The effects of a soluble activin type IIB receptor on obesity and insulin sensitivity

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks